Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2759MR)

This product GTTS-WQ2759MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2759MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1484MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ3744MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ4187MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ4039MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ10762MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ2364MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ12620MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ1873MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW